product name Resiquimod
Description: Resiquimod (also known as R-848, S-27609) is an immune response modifier that acts as a potent TLR 7/8 agonist. Resiquimod is the analogue of imiquimod (also called R-837,S-26308). Resiquimod has been reported to dose-dependently induce some cytokines including IFN, TNF, IL-1β and IL-6 in human peripheral blood mononuclear (PBMCs). In addition, Resiquimod has been revealed to stimulate intracellular IL-1βincreased approximately 15%. The results have also been noted that both monocytes and B cells produced IFN in response to Resiquimod.
References: Nat Immunol. 2002 Feb;3(2):196-200; J Immunol. 2003 Oct 15;171(8):4320-8.
314.38
Formula
C17H22N4O2
CAS No.
144875-48-9
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 63 mg/mL (200.4 mM)
Water: <1 mg/mL
Ethanol: 21 mg/mL (66.8 mM)
Solubility (In vivo)
Synonyms
R-848
other peoduct :
| In Vitro |
In vitro activity: Resiquimod activates immune cells and induces proliferation of wild-type splenocytes via the Toll-like receptor 7 (TLR7)-MyD88-dependent signaling pathway. Resiquimod also modulates dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses. Resiquimod induces the differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells, and may improve cancer immunotherapy by reducing immunosuppressive MDSCs. Kinase Assay: Cell Assay: Unlike LPS-induced activation, which was MyD88-independent, Resiquimod-induced activation of NF-κB was completely dependent on MyD88. It was implied that Resiquimod activated macrophages via TLRs. |
|---|---|
| In Vivo | In wild-type mice, Resiquimod (50 nmol, i.p.) induces increased serum concentrations of IFN-alpha, TNF-alpha and IL-12, while neither TLR7-deficient mice nor MyD88-deficient mice show an increase in these cytokines. In a murine model of allergic asthma, Resiquimod (i.n., 20 μg/mouse) reduces allergen induced airway reactivity and inflammation via reduction in Nrf2 signaling. |
| Animal model | Wild-type mice, TLR7-deficient mice, and MyD88-deficient mice |
| Formulation & Dosage | Dissolved in saline; 50 nmol; i.p. injection |
| References | Nat Immunol. 2002 Feb;3(2):196-200; J Immunol. 2003 Oct 15;171(8):4320-8. |
